Market Overview

UPDATE: Piper Jaffray Raises PT to $24 on NuVasive; Q4 Sets Stage for Outperformance

Related NUVA
NuVasive Announces Acquisition Of Ellipse Technologies, Notes 'Potential To Become The Standard Of Care'
Benzinga's Top Upgrades
NuVasive reports Q4 and FY15 results (Seeking Alpha)

Piper Jaffray maintained NuVasive (NASDAQ: NUVA) with an Overweight rating and raised the price target from $23.00 to $24.00.

Piper Jaffray noted, "Management delivered surprising upside on a nice bounce-back in revenues in 4Q12. However, the challenge for NuVasive going forward will be to string together 3-4 quarters of meeting or beating estimates and to drive growth into the double-digit range that management has framed out for investors as an aspirational long-term objective, which, based on management's comments, will require continued cooperation from the spine market in terms of further improvements in growth. … We do in fact expect continued improvements in spine market growth in 2013 and we remain buyers of NUVA at current levels."

NuVasive closed at $18.42 on Tuesday.

Latest Ratings for NUVA

Dec 2015Bank of AmericaUpgradesUnderperformNeutral
Oct 2015Leerink SwannMaintainsOutperform
Oct 2015Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for NUVA
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (NUVA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters